A case-control study on the effect of hormone replacement therapy on ischaemic heart disease

British Journal of General Practice

Volumn 53, Issue 488, 2003, Pages 191-196

  Hippisley Cox, Julia ^a   Pringle, Mike ^a   Crown, Nicola ^b   Coupland, Carol ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Collingham Medical Centre ^*  (United Kingdom)

Author keywords

Coronary heart disease; Hormone replacement therapy; Ischaemic heart disease; Risk; Women

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; HORMONE;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL TRIAL; COMPUTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MEGADOSE; EPIDEMIOLOGY; ESTROGEN THERAPY; FEMALE; GENERAL PRACTICE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; INDIVIDUAL BASED POPULATION MODEL; INFORMATION PROCESSING; INTERVIEW; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; OUTCOMES RESEARCH; POPULATION RESEARCH; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SMOKING; TOPICAL DRUG ADMINISTRATION; UNITED KINGDOM;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; AGED; BODY MASS INDEX; DOSE-RESPONSE RELATIONSHIP, DRUG; ENGLAND; EPIDEMIOLOGIC METHODS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; MYOCARDIAL ISCHEMIA;

EID: 0037335022     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Michaelsson K, Baron JA, Farahmand BY, et al. Hormone replacement therapy and risk of hip fracture: Population based case-control study. The Swedish Hip Fracture Study Group. BMJ 1998; 316: 1858-1863.
2. Stampfer M, Colditz G. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiological evidence. Prev Med 1991; 20: 47-63.
3. Grodstein F, Stampfer M, Manson J, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-461.
4. Grodstein F, Manson J, Colditz G, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933-941.
5. Posthuma W, Westendrop R, Vandenbroucke J. Cardioprotective effect of hormone replacement therapy in postmenopausal women: Is the evidence biased? BMJ 1994; 308: 1268-1269.
6. Rodstrom K, Bengtsson C, Lissner L, Bjorkelund C. Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: Prospective cohort study in Gothenburg, Sweden. BMJ 1999; 319: 890-893.
7. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: Pooled data from clinical trials. BMJ 1997; 315: 149-153.
8. Barrett-Connor E. Hormone replacement therapy. BMJ 1998; 317: 457-461.
9. Khaw KT. Hormone replacement therapy again. Risk-benefit relation differs between populations and individuals. BMJ 1998; 316: 1842-1844.
10. The Writing Group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199-208.
11. Medical Research Council's General Practice Research Framework. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. BMJ 1996; 312: 473-478.
12. Women's Health Initiative. Women's Health Initiative Update: What You Should Know About Hormones and Cardiovascular Health. Bethesda, MA: Women's Health Initiative, 2000.
13. Hulley SMD, Grady DMD, Bush TP, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-613.
14. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522-529.
15. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative re-analysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047-1059.
16. Pettiti D, Sidney S, Perlman J. Increased risk of cholecystectomy in users of supplemental estrogen. Gastroenterol 1988; 94: 91-95.
17. Grady D, Hulley S, Furberg C. Venous thromboembolic events associated with hormone replacement therapy. [Letter]. JAMA 1997; 278: 477.
18. Hammersley V, Hippisley-Cox J, Wilson A. A comparison of research general practices and their patients with other practices - Cross-sectional survey in Trent. Br J Gen Pract 2002; 52: 463-468.
19. Hippisley-Cox J, Hammersley V, Pringle M, et al. How useful are general practice databases for research? Analysis of their accuracy and completeness in one research network. Submitted to the BMJ 2002.
20. Hammersley V, Meal A, Wright L, Pringle M. Using MIQUEST in general practice. J Informat Prim Care 1998; 1: 3-7.
21. Campbell N, Thain J, Deans H, et al. Secondary prevention in coronary heart disease: Baseline survey of provision in general practice. BMJ 1998; 316: 1430-1434.
22. Whitelaw FG, Nevin SL, Milne RM, et al. Completeness and accuracy of morbidity and repeat prescribing records held on general practice computers in Scotland. Br J Gen Pract 1996; 46: 181-186.
23. Cannon P, Connell P, Stockley I, et al. Prevalence of angina as assessed by a survey of prescriptions for nitrates. Lancet 1988; i: 979-981.
24. Dupont W. Power calculations for matched case-control studies. Biometrics 1988; 44: 1157-1168.
25. Breslow NE, Day NE. Statistical Methods in Cancer Research. 1st Edition. Lyons: IARC Scientific Publications, 1987.